Longboard Pharmaceuticals
Biotechnology ResearchCalifornia, United States11-50 Employees
Longboard Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel medicines for neurological diseases, with an emphasis on centrally acting small molecules that selectively target specific GPCR receptors. Its lead program, bexicaserin, is an oral 5-HT2C receptor superagonist intended to act in the central nervous system, and the company is advancing this candidate toward a global Phase 3 program, alongside LP659, a modulator of sphingosine-1-phosphate receptors for potential rare neuroinflammatory conditions. The firm operates from La Jolla, California, and has a development portfolio aimed at translating years of GPCR research into therapies for neurorelated disorders. Longboard has reported topline results from a Phase 1b/2a study evaluating bexicaserin in developmental and epileptic encephalopathies, indicating recent clinical activity supporting continued exploration of its candidates. In addition to its core neuroscience focus, the company has engaged in collaboration activities, such as partnering with Beacon Biosignals to leverage biomarker insights in its research programs.
1-888-653-2347 
support@leadiq.com 
